GlassScriptPhysician profile
Nathaniel Messenger
NPI 1275273864
$1,470.35
in general payments reported to CMS, 2019-2025
19 companies · $667 in 2025
The $667 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $379 · 2024: $425 · 2025: $667.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,390 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,390.36 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $273.67 | 2023-2025 | Dupixent |
| Janssen Biotech, INC. | $248.96 | 2023-2025 | Tremfya |
| Genzyme Corporation | $157.90 | 2023-2025 | |
| Abbvie INC. | $128.34 | 2023-2025 | |
| Galderma Laboratories, L.P. | $68.11 | 2025 | Nemluvio |
| Kyowa Kirin, INC. | $66.42 | 2025 | |
| Organogenesis INC. | $63.09 | 2024-2025 | Puraply Wound Matrix |
| Biofrontera INC. | $57.67 | 2024-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Pfizer INC. | $56.49 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.95 | 2024-2025 | Spevigo |
| Helsinn Therapeutics (U.S.), INC. | $51.39 | 2023-2024 | Valchlor |
| Convatec INC. | $47.53 | 2025 | |
| Chiesi USA, INC. | $42.46 | 2024-2025 | Filsuvez |
| Lilly USA, LLC | $42.30 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| Fresenius Kabi USA, LLC | $28.81 | 2023 | Idacio |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $26.83 | 2024 | |
| Ucb, INC. | $22.26 | 2025 | Bimzelx |
| Omeza LLC | $18.25 | 2024 | |
| Amgen INC. | $13.92 | 2025 | Otezla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathaniel Messenger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.